IL‐9 Is Essential for ILC2‐Mediated but Not Th2‐ and Th17‐Cell‐Mediated Allergic Airway Inflammation in Mice
European Journal of Immunology · 2026
DOI: 10.1002/eji.70270 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2026. Verfasst von Nikolaos D Sidiropoulos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Health Sciences, ETH Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Interleukin-9, Th2 Cells, Asthma, Th17 Cells. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ETH Zürich Project SKINTEGRITY.CH, Swiss National Science Foundation, Eccellenza.
Abstract (Originalsprache)
Interleukin‐9 (IL‐9) has primarily been associated with type 2 immunity in health and disease. While its impact on innate lymphoid cells (ILC2s) is well known, the cellular targets and mechanisms underlying type 2 immunity remain incompletely understood. In this study, we report the generation of a mouse‐specific anti‐IL‐9 receptor (IL‐9R) antibody, enabling us to accurately map IL‐9R protein expression across various immune cell types. In naïve mice, IL‐9R was detectable in ILC2s, marginal zone B cells, and B1b cells. In allergic lung inflammation, a subset of CD4 + T cells faintly upregulated IL‐9R, whereas DCs, macrophages, eosinophils, and neutrophils remained IL‐9R‐negative. Functionally, IL‐9R was found to significantly contribute to ILC2 expansion, their effector cytokine production, and eosinophilia in the papain asthma model. However, in the context of acute and chronic HDM exposure, IL‐9R was dispensable for both allergic lung inflammation and CD4‐dependent memory‐type 2 responses. Using mixed bone marrow chimeras in which IL‐9R is selectively absent in T cells, we confirmed that IL‐9R signaling in T cells does not critically impact chronic Th2 and Th17 responses. Lastly, using mice selectively lacking ILC2s, we demonstrate that this population is the culprit of pathological type 2 immunity in the lung in both papain‐ and acute HDM‐induced asthma models. Together, our results establish that IL‐9 is a critical regulator of ILC2‐dependent type 2 immunity, while its effects on T cell‐dependent responses are minimal. These findings provide a foundation for future studies exploring the therapeutic modulation of IL‐9 signaling in allergy and other inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Health Sciences, ETH Zürich, Zürich, Switzerland.
- Institute of Physiology, University of Zürich, Zürich, Switzerland.
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
ORCID-Profile: Nikolaos D Sidiropoulos, Christoph Schlapbach, Christoph Schneider, Manfred Kopf
Förderung
- ETH Zürich Project SKINTEGRITY.CH
- Swiss National Science Foundation, Eccellenza
Zitieren
APA
Sidiropoulos, N. D., Ampenberger, F., Schlapbach, C., Schneider, C., & Kopf, M. (2026). IL‐9 Is Essential for ILC2‐Mediated but Not Th2‐ and Th17‐Cell‐Mediated Allergic Airway Inflammation in Mice. European Journal of Immunology. https://doi.org/10.1002/eji.70270
Vancouver
Sidiropoulos ND, Ampenberger F, Schlapbach C, Schneider C, Kopf M. IL‐9 Is Essential for ILC2‐Mediated but Not Th2‐ and Th17‐Cell‐Mediated Allergic Airway Inflammation in Mice. European Journal of Immunology. 2026. doi:10.1002/eji.70270
BibTeX
@article{Sidiropoulos2026,
author = {Sidiropoulos, Nikolaos D and Ampenberger, Franziska and Schlapbach, Christoph and Schneider, Christoph and Kopf, Manfred},
title = {IL‐9 Is Essential for ILC2‐Mediated but Not Th2‐ and Th17‐Cell‐Mediated Allergic Airway Inflammation in Mice},
journal = {European Journal of Immunology},
year = {2026},
doi = {10.1002/eji.70270}
}
EUVIMED